Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies. IBM is a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.
Company Details
- Employees
- 53
- Phone
- (617) 714-9759
- co****@****uro.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- abcuro.com
Abcuro, Inc Questions
Abcuro, Inc's helpline number is (617) 714-9759
Abcuro, Inc's website is abcuro.com
Abcuro, Inc's LinkedIn profile is https://www.linkedin.com/company/abcuro-inc
Abcuro, Inc has
53 employees.
View email and phone details for 53
employees at Abcuro, Inc.
Abcuro, Inc's industry is
Biotechnology Research
Abcuro, Inc's top competitors are
Helicore Biopharma,
Timberlyne Therapeutics,
Atalanta Therapeutics,
Advancell,
Tenvie Therapeutics,
Verdiva Bio,
Ouro Medicines,
Akero Therapeutics,
Newleos Therapeutics,
Kardigan.
Abcuro, Inc's support email address is corporate.contact@abcuro.com
Abcuro, Inc's categories are Biotechnology Research
